How OMNY Health™ Is Supporting the Fight Against MG

Sep 10, 2020

OMNY Health™ worked closely with an innovative pharmaceutical company to support the launch of its Myasthenia Gravis (MG) drug by providing data from two of its health system partners.

Compiling in-depth information from more than 30 of our partnered medical facilities, we delivered a snapshot of the real-world healthcare encounters and treatment experience for over 1,700 patients via a secure, de-identified dataset. The OMNY Health Insights professional services team delivered dashboards characterizing the patient journey from initial interaction points to ultimate diagnosis and treatment, a solution that the pharma company’s claims data supplier could not provide. 

Of note, the insights collected enabled deeper insights into both inpatient and outpatient settings, as well as the broad spectrum of medical specialists delivering the care. Not surprising, variation in care was identified across physician specialty.

Armed with this data, our customer has optimized access to its product for patients in need. The insights our team provided allowed their global rare disease experts to better understand patient journeys without compromising privacy. 

Funds from this engagement have already routed back to the participating health systems for reinvestment, empowering them to hire more staff, improve frontline staff salaries, address budget challenges, and invest in new medical equipment. 

To learn more about this story and how to partner with OMNY Health, please contact us.

By continuing to use the site, you agree to the use of cookies. More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below, then you are consenting to this.